Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Microbix Biosystems Inc. > Conventional wisdom says...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(80)
•••
Comment by Mbxwatcheron Oct 05, 2021 12:54pm
197 Views
Post# 33967474

RE:RE:RE:RE:RE:RE:Conventional wisdom says...

RE:RE:RE:RE:RE:RE:Conventional wisdom says...Just watched Cameron on the AdCap newsletter.
Seems optimistic about sales growth for 2022 mirroring that of 2021 with similar or improved margins.
He specifically mentioned the $1.70 targets from IA and KRC Insights, and certainly seemed comfortable with those targets.

I missed the announcement of the QAPS approvals to support Covid Viral Variants, which he indicated is spurring on further orders of QAPS.  Did not mention next Ontario VTM order, but did indicate that they had just finished shipping out the last of the first order in September.

Outlook continues to remain great. Hopefully the share prices catches up slightly with the optimism
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities